Frank Morich - 03 Feb 2023 Form 3 Insider Report for Isoray, Inc. (CATX)

Role
Director
Signature
/s/ Frank Morich
Issuer symbol
CATX
Transactions as of
03 Feb 2023
Net transactions value
$0
Form type
3
Filing time
13 Feb 2023, 15:33:01 UTC
Previous filing
05 Jan 2023
Next filing
23 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CATX Stock Options (right to buy) 03 Feb 2023 Common Stock 632,840 Direct F1, F2
holding CATX Stock Options (right to buy) 03 Feb 2023 Common Stock 474,631 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested as of 2/3/2023 due to acceleration as a result of merger of Viewpoint Molecular Targeting, Inc. into wholly owned subsidiary of Isoray, Inc. (the "Merger").
F2 Received in exchange for options to acquire 200,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.27 per share pursuant to the terms of the Merger.
F3 Received in exchange for options to acquire 150,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.13 per share pursuant to the terms of the Merger.